185 related articles for article (PubMed ID: 33353853)
1. A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer.
Sanna G; Pestrin M; Moretti E; Biagioni C; De Santo I; Gabellini S; Galardi F; McCartney A; Biganzoli L
Clin Breast Cancer; 2021 Aug; 21(4):e332-e339. PubMed ID: 33353853
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
Wang Z; Liu J; Ma F; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Li Q; Xu B
Breast Cancer Res Treat; 2021 Jul; 188(2):441-447. PubMed ID: 33895900
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046.
Krajnak S; Decker T; Schollenberger L; Rosé C; Ruckes C; Fehm T; Thomssen C; Harbeck N; Schmidt M
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3391-3400. PubMed ID: 33743073
[TBL] [Abstract][Full Text] [Related]
6. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
[TBL] [Abstract][Full Text] [Related]
8. Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).
Orlando L; Lorusso V; Giotta F; Di Maio M; Schiavone P; Fedele P; Quaranta A; Caliolo C; Ciccarese M; Cinefra M; Romito S; Pisconti S; Prete SD; Aieta M; Rizzi D; Maiello E; Colucci G; Cinieri S
Breast; 2020 Oct; 53():18-22. PubMed ID: 32540553
[TBL] [Abstract][Full Text] [Related]
9. Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.
Tan EH; Tan DS; Li WY; Haaland B; Ang MK; Chau NM; Toh CK; Tan IB; Koh TS; Thng CH; Chowbay B; Hui KM; Lim WT; Ng QS
Lung Cancer; 2015 Jun; 88(3):289-96. PubMed ID: 25896396
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
[TBL] [Abstract][Full Text] [Related]
11. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
12. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
[TBL] [Abstract][Full Text] [Related]
13. Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.
Steger GG; Dominguez A; Dobrovolskaya N; Giotta F; Tubiana-Mathieu N; Pecherstorfer M; Ardizzoia A; Blasinska-Morawiec M; Espinosa E; Villanova G
Clin Breast Cancer; 2018 Feb; 18(1):e41-e47. PubMed ID: 28666812
[TBL] [Abstract][Full Text] [Related]
14. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract][Full Text] [Related]
15. Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
El-Arab LR; Swellam M; El Mahdy MM
J Egypt Natl Canc Inst; 2012 Mar; 24(1):15-22. PubMed ID: 23587228
[TBL] [Abstract][Full Text] [Related]
16. The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
Montagna E; Pagan E; Cancello G; Sangalli C; Bagnardi V; Munzone E; Salè EO; Malengo D; Cazzaniga ME; Negri M; Peruzzotti G; Veronesi P; Viale G; Colleoni M
Anticancer Drugs; 2022 Jan; 33(1):e628-e634. PubMed ID: 34407044
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells.
Krajnak S; Loewe A; Battista MJ; Hasenburg A; Heimes AS; Schmidt M; Schwab R; Brenner W
Anticancer Res; 2021 Mar; 41(3):1243-1250. PubMed ID: 33788715
[TBL] [Abstract][Full Text] [Related]
18. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
20. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
Briasoulis E; Aravantinos G; Kouvatseas G; Pappas P; Biziota E; Sainis I; Makatsoris T; Varthalitis I; Xanthakis I; Vassias A; Klouvas G; Boukovinas I; Fountzilas G; Syrigos KN; Kalofonos H; Samantas E
BMC Cancer; 2013 May; 13():263. PubMed ID: 23718900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
